Search for dissertations about: "tuberculosis treatment"

Showing result 1 - 5 of 102 swedish dissertations containing the words tuberculosis treatment.

  2. 1. Interplay of human macrophages and Mycobacterium tuberculosis phenotypes

    Author : Johanna Raffetseder; Maria Lerm; Olle Stendahl; Vesa Loitto; Trude Helen Flo; Linköpings universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; NATURVETENSKAP; NATURAL SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Mycobacterium tuberculosis; tuberculosis; macrophage; innate immunity; host-pathogen interaction; antibiotic tolerance; phagosomal maturation; bacterial phenotype; dormancy; persistence; virulence factor; ESAT-6; ESX-1;

    Abstract : Mycobacterium tuberculosis (Mtb) is the pathogen causing tuberculosis (TB), a disease most often affecting the lung. 1.5 million people die annually due to TB, mainly in low-income countries. READ MORE

  4. 2. Epidemiological aspects of tuberculosis in Guinea-Bissau, West Africa

    Author : Per Gustafson; Enheten för infektionssjukdomar; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; tuberculin skin test; Infections; Infektioner; survival; mortality; case fatality rate; risk factor; incidence; Guinea-Bissau; Africa; epidemiology; Mycobacterium tuberculosis; HIV-2; HIV-1; HIV; Tbc; Tuberculosis; TB;

    Abstract : Tuberculosis (TB) has plagued the humanity for several thousands of years. The bacteria causing TB is mainly spread from person to person as an aerosol transmission. It is estimated that one third of the world’s population is infected with the disease; about 10% of these will develop active TB during their lifetime. READ MORE

  5. 3. Towards individualised treatment of tuberculosis

    Author : Katarina Niward; Thomas Schön; Jakob Paues; Judith Bruchfeld; Maria Lerm; Åse B. Andersen; Linköpings universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES;

    Abstract : Each year, around 10 million of individuals develop active tuberculosis (TB). Worldwide, TB is the leading cause of death from an infectious agent surpassing both malaria and HIV. READ MORE

  6. 4. Pharmacometric models to inform dose selection and study design : Applied in hemophilia and tuberculosis

    Author : Alan Faraj; Ulrika S. H. Simonsson; Joakim Nyberg; Ron Mathot; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; drug development; pharmacometrics; pharmacokinetics; pharmacodynamics; non-linear mixed effect models; hemophilia; tuberculosis; dose selection; study design; pediatric extrapolation;

    Abstract : While tuberculosis is a global pandemic, hemophilia is a rare disease which many have not heard of. Due to tuberculosis mainly being a problem in developing countries and hemophilia being a rare disease, they are not as heard of as other diseases such as cancer or metabolic diseases which are on the rise in Western societies. READ MORE

  7. 5. Novel Pharmacometric Methods for Informed Tuberculosis Drug Development

    Author : Oskar Clewe; Ulrika S.H. Simonsson; Mats O. Karlsson; Piet van der Graaf; Uppsala universitet; []
    Keywords : MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; pharmacokinetics; pharmacodynamics; PKPD; pharmacometric; nonlinear mixed-effects models; multistate tuberculosis pharmacometric model; general pharmacodynamic interaction model; general pulmonary distribution model; tuberculosis; rifampicin; isoniazid; ethambutol; Pharmaceutical Science; Farmaceutisk vetenskap;

    Abstract : With approximately nine million new cases and the attributable cause of death of an estimated two millions people every year there is an urgent need for new and effective drugs and treatment regimens targeting tuberculosis. The tuberculosis drug development pathway is however not ideal, containing non-predictive model systems and unanswered questions that may increase the risk of failure during late-phase drug development. READ MORE